OneTake AI | €1M | 🎥 Video Creation

Paris-based OneTake AI raised €1M to advance its conversational AI video editor, which allows users to edit videos by chatting or speaking to an AI agent. Aimed at entrepreneurs, coaches, and creators, OneTake simplifies professional video creation without needing editing skills. The funding will support product improvements, platform expansion, and the launch of their latest product: OneTake 7.

Astriis | €1.7M | ⚙️ Industrial Tech

The Grenoble-based predictive maintenance platform has raised €1.7 million to further development of vibration sensors to detect early mechanical issues in rotating machines. This tech helps prevent costly failures in hardware-dependent sectors like wind power, hydro, and heavy industry. The funds will support hiring, especially for the sales team.

BiznessMatch | €1.8M | 🤝 Networking

BiznessMatch raised €1.8 million to grow its AI-powered networking app and international club network. The platform helps business owners find partners or service providers based on needs and skills and claims to offer a faster, more targeted alternative to LinkedIn. The funding will boost AI development, translation tools, and expand physical networking clubs in Europe, North America, and Asia.

Allergen Alert | €3.6M | 🧪 Healthtech

Allergen Alert raised €3.6 million to bring to market a portable device that quickly detects food allergens and gluten. Born from the founder’s personal experience, the technology miniaturizes established player bioMérieux’s diagnostics to give individuals and professionals real-time allergen testing via a smartphone-connected tool.

Carb0n | €5M | 🌱 Climate

Carb0n raised €5 million from Batipart Europe to expand its platform helping commercial real estate owners monitor, manage, and reduce the carbon footprint of their buildings. Their tools support compliance with energy regulations and improve asset value through energy efficiency and solar installations.

Isentroniq | €7.5M | ⚛️ Quantum Computing

Paris-based Isentroniq raised €7.5 million to solve a major hardware bottleneck in scaling quantum computers. Their low-heat, space-saving wiring tech could allow machines to grow from hundreds to millions of qubits, cutting costs and enabling industrial-scale quantum computing.

Cartan Trade | €9M | 💼 Insurtech

Paris-based Cartan Trade raised €9 million to scale its trade credit insurance platform and expand across Europe. The platform helps companies protect themselves from unpaid invoices, offering digital insurance backed by major insurers like Scor and Intact. The funding also follows a change in ownership as Cartan enters a new growth phase.

EVerZom | €10M | 🧬 Biotech

Strasbourg-based EVerZom raised €10 million to launch clinical trials for its first exosome-based drug, EVerGel, targeting painful fistulas in Crohn’s disease. Exosomes are tiny particles that help cells communicate and could offer a new way to treat inflammation and regenerate tissue. The funds will also help EVerZom expand its exosome platform to other diseases and scale up manufacturing.

probabl. | €13M | 🤖 AI

Paris-based probabl. raised €13 million in a seed round to grow scikit-learn, the popular open-source machine learning library it now operates. Originally developed at French research institute Inria, scikit-learn powers AI at Spotify, Booking.com, and JP Morgan. Probabl is building commercial tools on top of it, like Skore—its enterprise support platform,while keeping the library free and open-source. Investors include Serena, Capital Fund Management, and Mozilla Ventures.

Step Pharma | €38M | 🧬 Biotech

Saint-Genis-Pouilly–based Step Pharma completed a €38 million Series C round to advance dencatistat, its lead cancer drug. The treatment blocks CTPS1, an enzyme cancer cells rely on to grow, while leaving healthy cells unharmed. The new funding, led by V-Bio Ventures with Bpifrance and others, will fund ongoing clinical trials for blood cancers, solid tumors, and a rare blood disorder called essential thrombocythaemia.

Adcytherix | €105M | 🧬 Biotech

Marseille-based biotech Adcytherix raised €105 million in a massive Series A round to develop a new generation of cancer drugs called antibody-drug conjugates (ADCs). These treatments work by attaching a cancer-killing compound to an antibody that seeks out tumor cells, delivering the drug directly where it’s needed while sparing healthy tissue. The company’s lead drug, ADCX‑020, is being prepared for clinical trials to treat cancers that no longer respond to current therapies. The funding, led by Bpifrance with several major European and U.S. investors, will also support research into new types of ADCs that use novel payloads to overcome drug resistance.